Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis

DOI: 10.1128/AAC.49.7.3028-3030.2005

Article Figures & Data

Open in new tab
Download powerpoint
FIG. 1.
Effects of administration of nebulized d-AMB versus intravenous administration of d-AMB in steroid-immunosuppressed rats with experimental invasive aspergillosis. *, significant relative to value for control.
Open in new tab
Download powerpoint
FIG. 2.
Effects of administration of nebulized L-AMB versus intravenous administration of L-AMB in steroid-immunosuppressed rats with experimental invasive aspergillosis. *, significant relative to value for control; †, significant relative to value for i.v. d-AMB; ‡, significant relative to value for nd-AMB.

TABLE 1.

Therapeutic efficacy in the treatment groups

Group	No. of rats	Value for rats surviving ≥5 days of treatment^b
Group	No. of rats	No. of rats (% of total)	Wt of paired lungs (g)^a	Amt of glucosamine/paired lungs (μg)^a	Log₁₀ no. of CFU/g^a
Control	23	11 (47.83)	3.15 (2.63-3.68)	176.25 (117.06-237.44)	5.08 (4.53-5.63)
d-AMB at 1 mg/kg/day, i.v.	25	17 (68)	2.97 (2.61-3.33)	148.36 (96.37-200.35)	5.07 (4.83-5.30)
L-AMB at 5 mg/kg/day, i.v.	27	19 (70.37)	2.37 (2.06-2.68)^*	78.26 (31.30-125.22)	4.99 (4.75-5.24)
nd-AMB at 1.13 mg/kg/day	18	15 (83.33)	2.26 (1.94-2.58)^*†	97.89 (40.18-155.60)	4.56 (4.14-4.97)
nL-AMB at 2.3 mg/kg/day	16	14 (87.5)	1.87 (1.60-2.14)^*†	28.31 (5.34-51.29)^*†	4.48 (3.80-5.17)
nL-AMB + L-AMB, i.v.	16	16 (100)	1.82 (1.59-2.05)^*†	46.28 (10.58-81.97)^*	4.30 (3.89-4.70)

↵a Results are expressed as means ± 95% confidence intervals. *, P ≤ 0.01 versus value for control; †, P ≤ 0.01 versus value for d-AMB administered i.v. at 1 mg/kg/day.
↵b Values are the results of three experiments combined.